Onderneming Kuros Biosciences AG Swiss Exchange
Aandelen
CH0325814116
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
CHF in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Medical Devices
100,0
%
| 13 | 73,8 % | 34 | 100,0 % | +153,03% |
Verkoop per regio
CHF in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
97,8
%
| 17 | 96,6 % | 33 | 97,8 % | +88,93% |
European Union
1,7
%
| 0 | 2,4 % | 1 | 1,7 % | +35,20% |
Other
0,4
%
| 0 | 1,0 % | 0 | 0,4 % | -17,82% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 04-12-17 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19-04-21 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 17-02-23 |
Chief Tech/Sci/R&D Officer | - | 01-01-17 | |
Sjoerd Musters
COO | Chief Operating Officer | - | 01-10-22 |
Luuk van Dijk
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-15 |
Katherine Sage
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-21 |
John Griffin
PRN | Corporate Officer/Principal | - | 12-10-23 |
Marcel Borger
LAW | General Counsel | - | 01-01-20 |
Philippe Saudan
PRN | Corporate Officer/Principal | 57 | 10-08-16 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 14-06-18 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19-04-21 |
Joost de Bruijn
FOU | Founder | 58 | 04-12-17 |
Chairman | 67 | 23-05-17 | |
Oliver Walker
BRD | Director/Board Member | 55 | 14-06-18 |
Leanna Caron
BRD | Director/Board Member | 56 | 16-06-16 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 36 866 049 | 23 857 779 ( 64,71 %) | 17 244 ( 0,0468 %) | 64,71 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
KUROS BIOSCIENCES AG 3.15% | 1 160 106 | 3.15% | 7 805 309 $ |
Bedrijfsgegevens
Sector
Verkoop per activiteit
Verkoop per regio
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,63% | 102 mld. | |
+1,62% | 96,29 mld. | |
+2,62% | 22,18 mld. | |
-16,67% | 21,2 mld. | |
-8,96% | 18,31 mld. | |
-38,74% | 17,38 mld. | |
-13,21% | 16,36 mld. | |
+5,41% | 13,97 mld. | |
+33,57% | 12,17 mld. |